ArticleKidney3602026
Integrated Study of Vancomycin-Induced Nephrotoxicity in the Context of Sepsis: Animal Models and Transcriptomics.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
key pointsVancomycin exacerbates kidney injury in a mouse model of LPS-induced sepsis. GFR is a more sensitive and earlier indicator of vancomycin-associated kidney injury than serum creatinine or BUN.
backgroundVancomycin (VAN) is widely used in sepsis but may exacerbate sepsis-associated AKI. The mechanisms by which VAN aggravates renal injury in the septic context remain unclear, and early functional changes are difficult to detect using conventional biomarkers.
methodsC57BL/6 mice were subjected to LPS-induced sepsis, VAN-induced nephrotoxicity, or combined injury. Renal function was continuously assessed using noninvasive percutaneous real-time GFR monitoring. Conventional renal injury markers, histopathology, and transcriptomic analyses were performed at 2, 24, and 72 hours.
resultsIn septic mice, VAN administration caused an early and marked decline in GFR, preceding increases in serum creatinine and BUN. Compared with sepsis alone, combined LPS and VAN treatment resulted in more sustained renal dysfunction and more severe tubular injury. Transcriptomic profiling identified early and persistent upregulation of TNF receptor superfamily, member 1a and sustained upregulation of C-C motif chemokine ligand 20 in the combined injury model. Functional enrichment analyses revealed activation of inflammatory and immune-related pathways, including TNF signaling, cytokine-cytokine receptor interaction, and immunoglobulin superfamily cell adhesion molecule signaling.
conclusionsReal-time GFR monitoring demonstrates that VAN exacerbates sepsis-associated AKI by inducing early functional impairment. Transcriptomic changes suggest that enhanced inflammatory signaling and immune cell recruitment contribute to VAN-aggravated renal injury in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.